Goldman Sachs Group Inc. issued a report on Bristol-Myers Squibb Co (NYSE:BMY), raising its target price to $75.00 earlier today
- Updated: October 14, 2016
Goldman Sachs Group Inc. increased the target price of Bristol-Myers Squibb Co (NYSE:BMY) to $75.00 indicating a possible upside of 0.49%.
On Tuesday September 20, 2016, Citigroup released a statement on Bristol-Myers Squibb Co (NYSE:BMY) dropped the target price from $75.00 to $70.00. At the time, this suggested an upside of 0.27%.
Having a price of $50.32, Bristol-Myers Squibb Co (NYSE:BMY) traded 0.26% higher on the day. The last stock price is down -24.14% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Bristol-Myers Squibb Co has recorded a 50-day average of $55.34 and a two hundred day average of $66.40. Trading volume was down over the average, with 5,215,264 shares of BMY changing hands under the typical 13,607,000
Bristol-Myers Squibb Co has a 52 week low of $49.12 and a 52 week high of $77.12 with a P/E ratio of 29.46 BMY’s total market value is presently $0.
A total of 21 brokers have issued a report on BMY. 0 firms rating the stock a strong buy, zero analysts rating the stock a buy, 0 brokerages rating the company a hold, zero firms rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $76.29.
Brief Synopsis About Bristol-Myers Squibb Co (NYSE:BMY)
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.